Tag: MTC HEA PHA BIO

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the...

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has...

Elysium Therapeutics to Participate in the 2025 BIO International Convention to Discuss Challenge of Fentanyl Rebound and Rescue Medication Designed for Synthetic Opioids

LYONS, Colo., June 5, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsMTC HEA PHA BIO

Alvopetro Announces June 2025 Sales Volumes

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

MTY Food Group Inc Will Hold a Conference Call to Discuss Its Second Quarter Results

Tag: MTC HEA PHA BIO

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

Elysium Therapeutics to Participate in the 2025 BIO International Convention to Discuss Challenge of Fentanyl Rebound and Rescue Medication Designed for Synthetic Opioids

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us